<DOC>
	<DOCNO>NCT00690638</DOCNO>
	<brief_summary>A Phase 3 , Randomized , Double-Blind , Placebo-Controlled , Multi-Center Study Evaluate Safety Efficacy PHX1149T Monotherapy Subjects Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>Safety Efficacy Study Dutogliptin/PHX1149T Treat Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus , drug na√Øve willing washout exist oral therapy BMI 25 48 kg/m2 , inclusive HbA1c 7.0 % 10.0 % , inclusive Age 18 75 year , inclusive Currently 3 oral antidiabetic drug insulin . Type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>dutogliptin</keyword>
	<keyword>PHX1149</keyword>
	<keyword>DPP4 inhibitor</keyword>
</DOC>